160 related articles for article (PubMed ID: 26053556)
1. Decreased elimination clearance of midazolam by doxorubicin through reductions in the metabolic activity of hepatic CYP3A in rats.
Nagai K; Yoshida N; Kiyama M; Kasahara K; Yamamura A; Konishi H
Xenobiotica; 2015; 45(10):874-80. PubMed ID: 26053556
[TBL] [Abstract][Full Text] [Related]
2. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam.
Fukuno S; Nagai K; Fujiike M; Sasaki Y; Konishi H
Xenobiotica; 2019 Dec; 49(12):1470-1477. PubMed ID: 30714842
[TBL] [Abstract][Full Text] [Related]
3. Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol.
Nagai K; Suzuki S; Yamamura A; Konishi H
Biopharm Drug Dispos; 2015 Apr; 36(3):174-82. PubMed ID: 25430017
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
[TBL] [Abstract][Full Text] [Related]
5. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of Action of Panaxytriol on Midazolam 1'-Hydroxylation and 4-Hydroxylation Mediated by CYP3A in Liver Microsomes and Rat Primary Hepatocytes.
He F; Zhang W; Zeng C; Xia C; Xiong Y; Zhang H; Huang S; Liu M
Biol Pharm Bull; 2015; 38(10):1470-7. PubMed ID: 26424012
[TBL] [Abstract][Full Text] [Related]
7. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
[TBL] [Abstract][Full Text] [Related]
8. Effect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats.
Kurosawa S; Uchida S; Ito Y; Yamada S
Xenobiotica; 2009 Feb; 39(2):162-70. PubMed ID: 19255942
[TBL] [Abstract][Full Text] [Related]
9. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat.
Eeckhoudt SL; Horsmans Y; Verbeeck RK
Xenobiotica; 2002 Nov; 32(11):975-84. PubMed ID: 12487727
[TBL] [Abstract][Full Text] [Related]
10. In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.
Saito Y; Nishimura Y; Kurata N; Iwase M; Aoki K; Yasuhara H
J Pharmacol Sci; 2011; 115(3):399-407. PubMed ID: 21358120
[TBL] [Abstract][Full Text] [Related]
11. Effect of carrageenan-induced acute peripheral inflammation on the pharmacokinetics and hepatic metabolism of midazolam in rats.
Kajikawa N; Doi M; Kusaba J; Aiba T
Drug Metab Pharmacokinet; 2014; 29(5):400-6. PubMed ID: 24717840
[TBL] [Abstract][Full Text] [Related]
12. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
14. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
[TBL] [Abstract][Full Text] [Related]
15. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.
Farkas D; Oleson LE; Zhao Y; Harmatz JS; Zinny MA; Court MH; Greenblatt DJ
J Clin Pharmacol; 2007 Mar; 47(3):286-94. PubMed ID: 17322140
[TBL] [Abstract][Full Text] [Related]
16. Effect of Chronic Kidney Disease on Hepatic Clearance of Drugs in Rats.
Tokunaga A; Miyamoto H; Fumoto S; Nishida K
Biol Pharm Bull; 2020; 43(9):1324-1330. PubMed ID: 32879206
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
[TBL] [Abstract][Full Text] [Related]
18. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
[TBL] [Abstract][Full Text] [Related]
19. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Hartwell PS; Raisys VA; Marsh CL; McVicar JP; Barr DM
J Pharmacol Exp Ther; 1994 Oct; 271(1):549-56. PubMed ID: 7965755
[TBL] [Abstract][Full Text] [Related]
20. UPLC-MS/MS analysis of the Michaelis-Menten kinetics of CYP3A-mediated midazolam 1'- and 4-hydroxylation in rat brain microsomes.
Venkatapura Chandrashekar D; DuBois B; Mehvar R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1180():122892. PubMed ID: 34388602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
